Inflation Reduction Act

News

Despite US policy changes, drug prices stay stubbornly high

US policy changes designed to curb drug prices seem ineffective, as the annual cost of new medicines still exceeds $250,000, curbing patient access.

Market Access

pharmaphorum podcast Episode 270, Alice Valder Curran, Hogan Lovells

Policy in Focus: What’s new with CMS drug price negotiation,...

Hogan Lovells partner Alice Valder Curran returned to elucidate some of the finer points of the latest communication from CMS.

News

SCOTUS won't hear pharma's IRA complaints

The US Supreme Court has refused to consider lawsuits from pharma groups challenging Medicare's drug pricing negotiation powers.

News

Poll finds Americans cutting back elsewhere to fund health

Many Americans are forced to make difficult trade-offs with living expenses and delay life events like retirement to afford health, says a new poll.

News

AZ takes Medicare negotiation appeal to SCOTUS

AstraZeneca has elevated its challenge to Medicare drug price negotiation powers to the Supreme Court of the US.

Market Access

Pharma go-to-market transformation: Why cross-functional sil...

Pharmaceutical go-to-market transformation has become the industry's most urgent priority, yet cross-functional coordination remains pharma's biggest challenge.

Despite US policy changes, drug prices stay stubbornly high

Policy in Focus: What’s new with CMS drug price negotiation,...

SCOTUS won't hear pharma's IRA complaints

Poll finds Americans cutting back elsewhere to fund health

AZ takes Medicare negotiation appeal to SCOTUS

Pharma go-to-market transformation: Why cross-functional sil...

Astellas pays $285m for Audax cancer drug, and other deals

Discover a new era of healthcare panel engagement: Grounded ...

Inflation Reduction Act

Editor's Picks